Research and Development Funding. The Licensee shall pay or reimburse (as applicable) Ascendis for the Research and Technical Development Plan Expenses in accordance with the schedule set forth in the Research and Technical Development Plans.
Research and Development Funding. (a) Within [**] days after the end of each Calendar Quarter, PTC shall provide an invoice to Roche for the Quarterly R&D Fees actually incurred during such Calendar Quarter, and in prior periods with respect to amounts not yet invoiced or paid, and Roche shall pay PTC such Quarterly R&D Fees within [**] days after receipt thereof.
(b) Roche shall not be obligated to pay Quarterly R&D Fee amounts in excess of [**] percent ([**]%) above the amounts set forth in the then-current Research Plan as approved by the JSC, or in the then-current SRA Development Plan or New Product Development Plan, as applicable, unless such amounts have been preapproved by Roche in writing.
(c) If the Foundation performs any work or provides or procures any services as set forth in the Research Plan, SRA Development Plan or New Product Development Plan, then the Foundation shall provide Roche with an invoice setting forth all costs incurred by the Foundation in connection with such work or services, including out-of-pocket costs, internal costs and a reasonable allocation of overhead, and providing reasonable documentation thereof, and Roche shall pay Foundation such invoiced amount within [**] days after receipt thereof.
Research and Development Funding. Research and development funding payments in the following amounts on the dates set forth below: PAYMENT PAYMENT DATE AMOUNT (US$) -------------------------------------- -------------- September 16, 1999 187,500 November 16, 1999 187,500 February 16, 2000 187,500 May 16, 2000 187,500 August 16, 2000 750,000 November 16, 2000 750,000 February 16, 2001 750,000 May 16, 2001 750,000 August 16, 2001 500,000 November 16, 2001 500,000 February 16, 2002 500,000 May 16, 2002 500,000 The payment amounts set forth above shall be guaranteed, non-refundable and non-creditable and shall be paid directly to Corixa, provided, however, (1) in the event that Corixa has not delivered to ZKC the data analysis of Corixa's US Phase II clinical trial of Licensed Product in the Licensed Field on or before August 2, 2000, ZKC's obligation to make the payment due under Section 5.1 on August 16, 2000 shall be delayed until two (2) weeks after ZKC's receipt of such data analysis (2) in the event ZKC elects to terminate this Agreement pursuant to Section 18.3 hereof, ZKC shall pay Corixa any and all amounts payable and still outstanding under this Section 5.1 as of the date of such termination, provided, however, that in the event such termination occurs after August 16, 2000 due to Corixa's delay in providing ZKC with the data analysis of Corixa's US Phase II clinical trial of Licensed Product in the Licensed Field, ZKC shall have no obligation to make any of the payments that were otherwise due under Section 5.1 on and after August 16, 2000 and (3) if ZKC shall elect to terminate this Agreement pursuant to Section 18.4 hereof, ZKC shall (i) in the event such termination occurs pursuant to Section 18.4(i), immediately pay Corixa $[*], less the amount ZKC has paid to Corixa under this Section 5.1 from August 16, 2000 up until that date and (ii) in the event such termination occurs pursuant to Section 18.4(ii), immediately pay Corixa $[*], less the amount ZKC has paid to Corixa under this Section 5.1 from August 16, 2001 up until that date. In any of the aforementioned instances, ZKC shall not be required to pay any amount that is due on a date -------- * Confidential treatment requested. after the termination notice is dispatched under this Section 5.1.
Research and Development Funding. Neurocrine and Rigel shall each be responsible for their own costs associated with activities within the Annual Research Plan.
Research and Development Funding. Licensee shall provide research and development funding to the CV Cancer Center until the commercialization of Product for the first indication as follows: [***] shall be paid to the CV Center within 30 days of the Effective Date and [***]. The monthly research and development payments shall be subject to adjustment annually by a percentage equal to the [***]. [***] Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Research and Development Funding. The Parties shall perform Development activities to develop and support Regulatory Approval of the Product pursuant to the Development Plan and Development Budget. Subject to the oversight of the GPT and endorsement by the JFC and compliance with the Development Plan:
(a) Bayer shall be solely responsible for, [***], all costs and expenses incurred in connection with the clinical Development of the Product (other than the [***] and Phase II Clinical Trials that are ongoing as of the Effective Date), the preparation and submission of regulatory filings for the Product, on a worldwide basis, further CMC development of Formulated Amikacin and the final packaging of the Product, obtaining and maintaining all Regulatory Approvals for the Product in the Shared Territory and in the Royalty Territory, and generally for the Commercialization of the Product. If Bayer does not take over clinical supply manufacturing of the Product, it will reimburse Nektar for costs of the Product formulation development activities as set forth in Exhibit 4.2(a)(iv).
(b) Nektar shall be solely responsible for, [***], all costs and expenses incurred in connection with all further Development of the Device conducted through completion of Phase III Clinical Trials.
(c) Each Party shall provide reasonable assistance and technical expertise as necessary to transfer appropriate technology to support Development of the Product under the Agreement. Such assistance may include the grant of appropriate rights of access and reference to regulatory filings to enable the Parties to assume responsibility for Development of the Product, and participation in meetings with regulatory agencies with respect to the Product. The costs and expenses of all such assistance and transfer of technical expertise by Nektar to Bayer shall be borne solely by Bayer.
(d) [***] Costs that are included in the Commercialization Plan and Commercialization Budget shall be included in Allowable Expenses; provided, however, that, if the portion of any [***] Costs for which Nektar is responsible according to its share of Product Profit and Loss pursuant to Section 8.2(b) that are included in the Commercialization Plan and Commercialization Budget exceeds [***], any additional [***] Costs shall not be included in Allowable Expenses and shall be borne solely by Bayer. Bayer shall solely bear any [***] Costs in the Royalty Territory, and any [***] Costs in the Shared Territory shall be included in Allowable Expenses.
Research and Development Funding. Medicis shall pay to Corixa research and development funding payments in the following amounts on the dates set forth below:
(a) The Effective Date $[***] [***] $[***] The payment amounts required to be made pursuant to Section 5.1 shall be [***] paid directly to Corixa when due and payable, [***].
Research and Development Funding. Partner will pay to AVEO for the research and development costs incurred by AVEO to fund activities directly in furtherance of Licensed Product clinical, regulatory and manufacturing process development in support of obtaining Marketing Approval (a) Two Million Five Hundred Thousand Dollars ($2,500,000) within fifteen (15) days of the Effective Date and provision of a valid tax invoice to Partner by AVEO for such amount (in the form of Exhibit E), and (b) Four Million Dollars ($4,000,000) upon XXX xxxxx of Marketing Approval for the RCC Indication. Partner shall notify AVEO of such approval promptly AVEO shall provide a valid tax invoice to Partner for such amount which shall be payable by Partner within fifteen (15) days of receipt of such invoice.
Research and Development Funding. Upon the execution of this Agreement, Bayer shall pay to Paravax a lump sum payment of US$[ ]. In addition, eight months, sixteen months and twenty-four months after the date of this Agreement Bayer shall pay to Paravax further lump sum payments of US$[ ] each. The total of such lump sum payments, US$[ ], shall be deemed to be funding for a portion of the research and development expenditures which Paravax has undertaken prior to the date of this Agreement. Bayer shall also make an initial advance research and development milestone payment of US$[ ] to Paravax upon the execution of this Agreement. Bayer shall make further research and development funding payments to Paravax as set forth on Exhibit A hereto upon completion of the milestones through the end of Phase II of the Research Program indicated on Exhibit A hereto. The specific dollar amounts set forth herein and on Exhibit A hereto are intended to be net of any withholding required upon transfer of funds to Paravax.
Research and Development Funding. Taiho shall pay to SUGEN the amounts set forth below to support SUGEN's research and development activities under the Collaboration during each year of the Collaboration Term. Such payments will be made on a [...***...], except that the amount due [...***...
